Manning & Napier Advisors
TAK icon

Manning & Napier Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Manning & Napier Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Sell
206,900
-12,077
-6% -$200K 0.04% 183
2026
Q1 		$4.06M Buy
218,977
+3,250
+2% +$57K 0.06% 173
2025
Q4 		$3.37M Sell
215,727
-10,711
-5% -$153K 0.04% 175
2025
Q3 		$3.32M Sell
226,438
-18,803
-8% -$279K 0.04% 184
2025
Q2 		$3.79M Sell
245,241
-52,282
-18% -$773K 0.05% 197
2025
Q1 		$4.42M Sell
297,523
-6,894
-2% -$96.6K 0.05% 173
2024
Q4 		$4.03M Sell
304,417
-13,524
-4% -$186K 0.05% 178
2024
Q3 		$4.52M Buy
317,941
+1,251
+0.4% +$17.7K 0.05% 194
2024
Q2 		$4.1M Buy
+316,690
New +$4.19M 0.05% 202

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Manning & Napier Advisors's TAK Position: Q2 2026 in Review

Manning & Napier Advisors reduced its Takeda Pharmaceutical (TAK) stake by 5.5% in Q2 2026, selling an estimated $200K and leaving 206,900 shares worth $3.32M. The position accounts for 0.04% of the portfolio, ranked #183.

Manning & Napier Advisors first reported a position in TAK in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.52M in Q3 2024. 379 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Manning & Napier Advisors held 206,900 shares of Takeda Pharmaceutical worth $3.32M as of Q2 2026.
  • Manning & Napier Advisors sold 12,077 Takeda Pharmaceutical shares in Q2 2026, an estimated $200K.
  • Takeda Pharmaceutical made up 0.04% of Manning & Napier Advisors's portfolio in Q2 2026, its #183 holding.
  • Manning & Napier Advisors first reported a position in Takeda Pharmaceutical in Q2 2024 and has held it in 9 quarters since.
  • Manning & Napier Advisors's Takeda Pharmaceutical position peaked at $4.52M in Q3 2024.
  • 379 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.